Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright

8 months ago 31

Skip to navigation Skip to main contented Skip to close file

TipRanks

Wed, February 25, 2026 astatine 9:10 AM CST 1 min read

H.C. Wainwright raised the firm’s price target connected Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy standing connected the shares. Phase 3 SELVA data, with the mLM-IGA superior endpoint demonstrating a statistically important 2.13-point mean change, is “a wide and decisive win,” says the analyst, who believes that the efficacy demonstrated successful the SELVA proceedings volition apt effect successful beardown and continued uptake among patients if approved.

Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected PVLA:

Disclaimer & DisclosureReport an Issue

Palvella Reports Positive Phase 3 Data for QTORIN Gel
Palvella Reports Positive Phase 3 Data for QTORIN
Palvella Therapeutics’ qtorin meets superior endpoint successful lymphatic malformations
Palvella Therapeutics (PVLA): Mechanistic Validation, Unmet Need, and Pivotal Trial Catalysts Underpin Buy Rating
Palvella Therapeutics absorption to conscionable virtually with Craig-Hallum

Read Entire Article